Intuitive Surgical 10-Qquarter ended 2026-09-30

Executive Summary

Intuitive Surgical sells and leases robotic-assisted surgical systems to hospitals, then earns recurring revenue from instruments, accessories and service. It is broadening minimally invasive care through da Vinci 5, single-port surgery and Ion lung biopsy, supported by training and digital offerings. Q3 procedure growth of 14% helped drive revenue growth of 22%, showing continued adoption despite slower procedure growth than in the prior-year comparison. A $450M antitrust settlement charge pushed quarterly earnings lower despite higher gross margins. International adoption offers expansion potential, but upcoming instrument-price reductions will test whether procedure growth can sustain earnings momentum.

What's Happening in the Business

• Da Vinci expansion: Q3 placements increased to 546 from 427, including 315 da Vinci 5 systems. The da Vinci 5 installed base reached 2,023, but only 177 were outside the United States, leaving international adoption at an earlier stage.

• Procedure demand: International da Vinci procedures grew 20%, vs 10% in the United States, where general surgery and gynecology led growth. Bariatric procedures declined at a low-double-digit rate, while China and South Korea were relative weak spots.

• Broader applications: Ion lung-biopsy procedures grew 31% to ≈49,700. Additional da Vinci 5 clearances and single-port certification for transvaginal gynecologic procedures expand potential uses, although adoption still requires clinical experience and regulatory progress.

• Access and distribution: Operating leases accounted for 53% of da Vinci placements, reducing hospitals’ upfront commitment while deferring Intuitive’s revenue. The ≈$533M acquisition of distributors in Southern Europe brings customer relationships directly into the company.

• Pricing changes: Management expects China’s national pricing framework to lower instrument prices beginning Q4 2026. Extended instrument use and volume pricing planned for 2027 are expected to reduce da Vinci instruments-and-accessories revenue per procedure by ≈3%–5% when fully implemented, excluding mix effects.

Key Financial Highlights

• Recurring revenue: Instruments, accessories, service and operating leases contributed 84% of quarterly revenue, tying much of the business to installed-system use rather than new-system purchases.
• Margin quality: Q3 tariff refunds reduced costs by $27.8M, exceeding $23.4M of tariff expense; margin expansion therefore included a benefit that should not be treated as recurring operating improvement.
• Investment and taxes: Q3 R&D rose 24% to $408M for product development and staffing. The nine-month effective tax rate increased to 18.4% from 11.8%, partly because prior-year tax benefits did not recur.
• Cash conversion: Nine-month capital expenditure was $329M. Other liabilities supplied $632M of operating cash, while inventory absorbed $822M to support growth, leasing and supply resilience; reported cash conversion is not solely an earnings-growth story.
• Capital return: Nine-month repurchases totaled $4.45B, while shares outstanding fell 2.4%, from 355M to 347M, net of issuance. Stock-based compensation before tax was $642M, including $104M capitalized; repurchases exceeded free cash flow.

Risk Assessment

• Legal and aftermarket exposure: The EndoWrist settlement remains subject to court approval and includes injunctive relief, while a separate instrument-repair antitrust case continues; lower-priced third-party instruments and unauthorized servicing threaten recurring revenue and product reputation.
• Pricing and China access: Planned instrument-price reductions pressure revenue per procedure, while tender uncertainty and domestic competition constrain Chinese system placements.
• Hospital funding and utilization: Budget and staffing constraints can limit purchases and procedures, and usage-based leases expose Intuitive to low utilization or cancellation.
• Supply and trade: Single-source components and cross-border manufacturing expose system availability and margins to shortages, tariffs and uncertain refunds.

This 10-Q lists only the risk factors that changed since the annual report. Full list: FY2025 10-K.

What to Watch

• Da Vinci 5 adoption: International deployment remains early. Broader placements accompanied by procedure growth would validate expansion; installations without increased use would weaken its recurring-revenue potential.
• Ion utilization: Procedure growth currently exceeds installed-base growth. Continued gains would support lung-biopsy adoption; slower use despite additional systems would signal weaker uptake.
• Instrument pricing: Watch revenue per procedure as China pricing changes and 2027 programs take effect. Procedure growth and product mix could offset lower prices; falling revenue per procedure without sufficient volume growth would pressure returns.
• Earnings and cash quality: Future margins should demonstrate progress beyond tariff refunds, while cash generation should remain supported by earnings rather than continued liability accumulation.